



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/435, C07D 453/02</b>		A1	(11) International Publication Number: <b>WO 98/00138</b> (43) International Publication Date: <b>8 January 1998 (08.01.98)</b>
<p>(21) International Application Number: <b>PCT/US97/11258</b></p> <p>(22) International Filing Date: <b>27 June 1997 (27.06.97)</b></p> <p>(30) Priority Data: 60/020,730 1 July 1996 (01.07.96) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): SEPRACOR, INC. [US/US]; 111 Locke Drive, Marlborough, MA 01752 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): FABIANO, Vincent, L. [US/US]; 9 Old Connecticut Path, Westborough, MA 01581 (US). McCULLOUGH, John, R. [US/US]; 6 Davidson Road, Worcester, MA 01605 (US).</p> <p>(74) Agents: CLEMENT, Candice, J. et al.; Heslin &amp; Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12203 (US).</p>		<p>(81) Designated States: US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b>  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: <b>METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (R)-CLIDINIUM</b></p> <p>(57) Abstract</p> <p>A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R)-clidinium. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of the (S)-clidinium enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Methods and Compositions For Treating Urinary Incontinence Using  
Enantiomerically Enriched (R)-Clidinium**

**Field of the Invention**

The present invention relates to methods for treating urinary incontinence, such as  
5 incontinence caused by bladder detrusor muscle instability, and to pharmaceutical  
compositions for such treatment.

**Background of the Invention**

Urinary incontinence is a prevalent problem that affects people of all ages and  
levels of physical health, both in healthcare settings and in the community at large. At  
10 present, urinary incontinence afflicts 15-30% of elderly people living at home, one-third  
of those living in acute-care settings, and at least one-half of those in long-term care  
institutions (R.M. Resnick, *Lancet* 346:94 (1995)). Medically, it predisposes persons to  
urinary tract infections, pressure ulcers, perineal rashes, and urosepsis. Psychosocially,  
urinary incontinence is associated with embarrassment, social stigmatization, depression,  
15 and with the risk of institutionalization (Herzo *et al.*, *Annu. Rev. Gerontol. Geriatr.*, 9:74  
(1989)). Economically, the costs are great; in the United States alone, over \$10 billion is  
spent per annum managing incontinence.

Treatments for incontinence include drugs with bladder relaxant properties, *i.e.*,  
which help to control bladder detrusor muscle overactivity. Such drugs are effective in 80  
20 to 85% of patients with uninhibited bladder contractions, with anticholinergic medications  
representing the mainstay of this type of treatment. For example, anticholinergics such as  
propantheline bromide, and combination smooth muscle relaxant/anticholinergics such as  
racemic oxybutynin and dicyclomine, have been used to treat urge incontinence. (*See,*  
*e.g.*, A.J. Wein, *Urol. Clin. N. Am.*, 22:557-77 (1995).)

25 No treatment for incontinence, including existing drug therapies, has achieved  
complete success with all classes of incontinent patients, and without significant side  
effects. For example, adverse effects, such as drowsiness, dry mouth, constipation,  
blurred vision, headaches, and cardiac arrhythmia which are related to the anticholinergic  
activity of drugs such as racemic oxybutynin, occur frequently and can be sufficiently  
30 troublesome to necessitate discontinuing treatment in up to 25% of patients, depending on  
the dosage. Yet, despite the occurrence of unwanted anticholinergic effects in many

patients, and an apparent lack of efficacy in the elderly institutionalized population, racemic oxybutynin nevertheless is considered the drug of first choice in patients with bladder detrusor muscle hyperactivity when pharmacological therapy is indicated (cf. Yarllur *et al.*, *Drugs Aging*, **6**:243 (1995)).

5 Another anticholinergic drug, clidinium, 3-hydroxy-1-methyl quinuclidinyl benzilate, is described in the literature for use as adjunctive therapy in peptic ulcer disease, and has been used in muscarinic receptor labeling studies (Brunner *et al.*, *Brit. J. Pharmacol.*, **102**:373-380 (1991); Waelbroeck *et al.*, *Mol. Pharmacol.*, **40**:413-420 (1991); Lambrecht, *Arzniem.-Forsch.*, **30**(II):2113-2115 (1980). Similar adverse effects 10 arising from the anticholinergic activity of clidinium are described in the literature (Cf. Physician's Desk Reference, 50th Edition, pages 2181-2182 (1996)).

#### Summary of the Invention

The present invention provides methods and compositions for treatment of urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress 15 incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostatectomy incontinence, with (R)-clidinium. The methods of the present invention provide for treatment of incontinence with fewer adverse effects than occur upon administration of racemic clidinium.

One aspect of the present invention relates to methods for treating urinary 20 incontinence by administration to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof. In a preferred embodiment of this method, the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, is substantially free of (S)-clidinium.

The present invention also relates to methods for treating bladder detrusor muscle instability comprising administration to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof. Preferably, the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, is substantially free of (S)-clidinium. 25

Another aspect of the present invention relates to pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)-

clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In a preferred embodiment, the pharmaceutical compositions of the present invention comprise (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)-clidinium.

5 The present invention also provides for formulating the pharmaceutical compositions of the present invention, comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in pharmaceutical unit dosage forms, including, e.g., tablets and soft elastic gelatin capsules.


10 Yet another embodiment of the present invention relates to a kit for treating urinary incontinence, such as bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostectomy incontinence, wherein said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, 15 and a pharmaceutically acceptable carrier, and instructions for administering the same while reducing or eliminating anticholinergic adverse effects associated with administration of racemic clidinium, or other incontinence drugs with anticholinergic action. Preferably, the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, is substantially free of (S)-clidinium.

20 Detailed Description of the Invention

It is known that urinary incontinence can be caused by uncontrolled or unstable bladder contractions, particularly of the bladder detrusor muscle which serves to force fluids out of the bladder. The major proportion of the neurohumeral stimulus for physiologic bladder contraction is acetylcholine-induced stimulation of postganglionic 25 muscarinic receptor sites on bladder smooth muscle. Consistent with this observation, most pharmacologic treatments for incontinence associated with uninhibited bladder contractions include medications with anticholinergic and smooth muscle relaxant properties. However, as set out above, many of the anticholinergic agents which have been used for the treatment of incontinence often have adverse effects associated with 30 their anticholinergic actions, which result in at least periodic discontinuation of use in a significant portion of the treated population.

The present invention relates to compositions and methods for the treatment of bladder instability in mammals, such as humans. More specifically, this invention provides enantiomerically enriched preparations of (R)-clidinium and methods for their use in the treatment of urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostatectomy incontinence. One feature of the subject non-racemic preparations of (R)-clidinium derives from the enantiomer's pharmacological advantage over the racemate in terms of its principal therapeutic and side effect profile. Certain deleterious local and/or systemic adverse effects of the racemic mixture, e.g., drowsiness, 5 xerostomia, mydriasis, constipation, cycloplegia, cardiac arrhythmia and/or epistaxis may 10 be reduced through treatment with enantiomerically enriched (R)-clidinium.

The chemical structure of (R)-clidinium is as set forth in Formula I:



15 In one aspect, the present invention provides a method for treating urinary incontinence using (R)-clidinium, which results in a reduction of the adverse effects associated with administration of racemic clidinium. The method comprises administering to a patient in need thereof a pharmaceutically effective amount of (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)-clidinium. In a preferred embodiment, the methods of the present invention are used to 20 treat urinary incontinence due to bladder detrusor muscle instability. Such instability may result in, for example, stress incontinence or urge incontinence, or combination thereof, and/or enuresis.

25 In another aspect, the present invention provides pharmaceutical compositions which comprise an enantiomerically enriched preparation of (R)-clidinium, or a pharmaceutically acceptable salt thereof, formulated together with one or more

pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for oral administration, parenteral administration, or topical application.

5 For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner. With respect to the 10 nomenclature of a chiral center, the terms "S" and "R" configuration are as defined by the IUPAC 1974 Recommendations for Section E., Fundamental Stereochemistry, *Pure Appl. Chem.*, 45:13-30 (1976). The terms racemate and enantiomer will be used in their normal context to describe the stereochemistry of clidinium preparations.

The terms "enantiomerically enriched" and "non-racemic", as used 15 interchangeably herein with reference to preparations of clidinium, refer to clidinium compositions in which the (R)-clidinium enantiomer is enriched, compared to a control mixture of (R)-clidinium and (S)-clidinium enantiomers. Unless otherwise specified, such terms refer to clidinium compositions in which the ratio of (R)-clidinium to (S)-clidinium enantiomers is greater than 1:1 by weight. For instance, an enantiomerically enriched 20 preparation of (R)-clidinium, means a preparation of clidinium having greater than 50% by weight of the (R)-clidinium enantiomer relative to the (S)-clidinium enantiomer, more preferably at least 75% by weight, and even more preferably at least 80% by weight. Of course, the enrichment can be much greater than 80% by weight, providing a "substantially enantiomerically enriched" or a "substantially non-racemic" preparation, 25 which refers to preparations of clidinium which have at least 85% by weight of the (R)-clidinium enantiomer relative to the (S)-clidinium enantiomer, more preferably at least 90% by weight, and even more preferably at least 95% by weight. The term "substantially free of (S)-clidinium" will be understood to have similar purity ranges., i.e., at least 85% by weight of the (R)-clidinium enantiomer relative to the (S)-clidinium 30 enantiomer, more preferably at least 90% by weight, and even more preferably at least 95% by weight.

The term "adverse effects" as used herein, refers to effects associated with administration of racemic clidinium, which are not part of the desired therapeutic effect of the drug. With respect to the treatment of urinary incontinence, such adverse effects, include, for illustrative purposes, drowsiness, epistaxis, xerostomia, mydriasis, 5 cycloplegia, unstable cardiovascular status such as arrhythmia (e.g., tachycardia or palpitations), increased ocular pressure, nausea, constipation, decreased sweating, impotence, and/or dermal manifestations such as urticaria.

The term "epistaxis" refers to nosebleeds, e.g., hemorrhage from the nose. Epistaxis is a side effect of anticholinergics in children.

10 The term "xerostomia" refers to dryness of the mouth due to lack of normal secretion.

The term "mydriasis" refers to dilation of the pupil, and often results in blurred vision.

15 The term "cycloplegia" refers to paralysis of the ciliary muscle; paralysis of accommodation.

The term "enuresis" refers to the involuntary discharge of urine, and "nocturnal enuresis" refers to involuntary discharge of urine during sleep at night.

Separation of enantiomers can be accomplished in several ways known in the art. For example, a racemic mixture of two enantiomers can be separated by chromatography 20 using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography", W.J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereometric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereometric salts can be formed by addition of 25 enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereometric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, 30 such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.

In addition to separation techniques such as those described above, the active enantiomer of clidinium can be synthesized by stereospecific synthesis to produce only the desired optical isomer using methodology well known to those skilled in the art. Chiral synthesis can result in products of high enantiomeric purity. However, in some 5 cases, the enantiomeric purity of the product is not sufficiently high. The skilled artisan will appreciate that the separation methods described above can be used to further enhance the enantiomeric purity of clidinium obtained by chiral synthesis.

The optical purity of the (R)-clidinium can be determined by methods known in the art. For example, a sample of the clidinium can be analyzed by high performance 10 liquid chromatography on a chiral chromatographic column. Another method of determining optical purity involves making a chiral ester, such as a Mosher ester, of a clidinium sample, and analyzing the NMR spectrum for the presence of the undesired enantiomer.

In preferred embodiments, (R)-clidinium is substantially free of (S)-clidinium. 15 "Substantially free" as used herein, means that at least 85% by weight of the total clidinium present is the (R)-clidinium enantiomer; more preferably at least 90% by weight, and still more preferably at least 95% by weight is the (R)-clidinium enantiomer. In a more preferred embodiment, at least 99 % by weight of the total clidinium present is the (R)-clidinium enantiomer.

20 (R)-clidinium can be used to treat urinary incontinence, including, *e.g.*, bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, and post-prostatectomy incontinence, by administration to a patient according to any suitable route of administration. (*See, Remington: The Science and Practice of Pharmacy*, Nineteenth Edition, Chapters 83-95 (1995).) For example, a preferred method 25 of administration is oral administration. Another preferred route of administration is intravenous administration. A particularly preferred route of administration is intravesical delivery, *i.e.*, administration directly to the bladder, *e.g.*, by injection or infusion.

According to the present invention, (R)-clidinium is preferably administered as a 30 pharmaceutical formulation (composition). The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact

with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As set out above, (R)-clidinium contains a quaternary amino functional group, 5 and thus is capable of forming pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic salts of (R)-clidinium. These salts can be prepared *in situ* during the final isolation and purification of the (R)-clidinium. Representative salts include the bromide, chloride, hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, 10 acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate salts and the like. (See, e.g., Berge *et al.*, "Pharmaceutical Salts", *J. Pharm. Sci.*, 66:1-19 (1977).)

Formulations of the present invention include those suitable for oral, nasal, topical 15 (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which is combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, and the particular mode of administration. The amount of 20 active ingredient which may be combined with a carrier material to produce a single dosage form preferably will be that amount of (R)-clidinium which produces a therapeutic effect. Generally, the amount of the active ingredient will range from about 1 % to about 99 % of the total formulation, preferably from about 5 % to about 70 %, and most preferably from about 10 % to about 30 %.

25 Methods of preparing these formulations or compositions include the step of bringing into association (R)-clidinium with a pharmaceutically acceptable carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association (R)-clidinium with liquid carriers, or finely divided solid carriers, or both, and any optional accessory ingredients, and then, 30 if necessary, shaping the product.

The phrase "pharmaceutically acceptable carrier" as used herein means a

pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the (R)-clidinium from one organ, or portion of the body, to another organ or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

5 Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) 10 gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) 15 alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations (*see, Remington: The Science and Practice of Pharmacy*, Nineteenth Edition, Chapter 80 (1995).)

20 Formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as a gelatin and glycerin, or sucrose and acacia), or as soft elastic gelatin capsules, and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as 25 an active ingredient. (R)-clidinium may also be administered as a bolus, electuary or paste.

30 In solid dosage forms of the present invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or may also be mixed with one or more of any of the following: (1) fillers

or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain 5 silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) 10 coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

15 Release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions of the present invention. Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like; (2) oil-soluble antioxidants, such as 20 ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

25 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), and/or surface-active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered (R)-clidinium moistened with an 30 inert, liquid diluent.

The pharmaceutical compositions of the present invention may also be formulated in a soft elastic gelatin capsule unit dosage form by using conventional methods, well-known in the art (see, e.g., Ebert, *Pharm. Tech.*, 1(5):44-50(1977)). Soft elastic gelatin capsules have a soft, globular, gelatin shell somewhat thicker than that of hard gelatin capsules, wherein a gelatin is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The hardness of the capsule shell may be changed by varying the type of gelatin and the amounts of plasticizer and water. The soft gelatin shells may contain a preservative to prevent the growth of fungi, such as methyl- and propylparabens and sorbic acid. The active ingredient may be dissolved or suspended in a liquid vehicle or carrier, such as vegetable or mineral oils, glycols such as polyethylene glycol and propylene glycol, triglycerides, surfactants such as polysorbates, or a combination thereof.

The tablets, and other dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art.

The pharmaceutical compositions of the present invention may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may also be administered by controlled release means and delivery devices such as those in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,796; and PCT published application WO92/20377.

The pharmaceutical compositions of the present invention may also optionally contain opacifying agents and may be formulated such that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration of (R)-clidinium include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert

5 diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions of the present invention can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

10 Suspensions, in addition to the active (R)-clidinium, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

15 Formulations of the pharmaceutical compositions of the present invention for rectal and vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate. Such formulations of the present invention are solid at room temperature, but liquid at body temperature and, therefore, will melt in the 20 rectum or vaginal cavity and release the active (R)-clidinium.

Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

25 Dosage forms for the topical or transdermal administration of (R)-clidinium include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

30 Formulations of the present invention in the form of ointments, pastes, creams and gels may contain, in addition to (R)-clidinium, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives,

polyethylene glycols, silicones, bentonites, silicic acid, talc and/or zinc oxide, or mixtures thereof.

5 Powders and sprays may contain, in addition to (R)-clidinium, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as, for example, chlorofluorohydrocarbons, volatile unsubstituted hydrocarbons, hydrocarbon ethers and compressed gases.

10 Transdermal patches have the added advantage of providing controlled delivery of the active (R)-clidinium of the present invention to the body. Such dosage forms may be made by dissolving or dispersing the (R)-clidinium in the proper medium. Absorption enhancers may also be used to increase the flux of the (R)-clidinium across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the (R)-clidinium in a polymer matrix or gel.

15 Regardless of the route of administration selected, the pharmaceutical compositions of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Where necessary, the pharmaceutical compositions of the present invention are sterile or can be sterilized before administration to a patient.

20 In a preferred embodiment, the enantiomerically enriched clidinium compositions of the present invention are provided in tablet or capsule form with, as inactive ingredients, dibasic calcium phosphate, lactose, magnesium stearate, providone and sodium starch glycolate. The capsules or tablets are preferably formulated with from about 0.25 mg to about 250 mg of (R)-clidinium, more preferably with from about 0.50 mg to about 100 mg of (R)-clidinium, and even more preferably with from about 1 mg to 25 about 50 mg of (R)-clidinium.

25 In another preferred embodiment, the enantiomerically enriched (R)-clidinium preparations of the present invention are provided in soft elastic gelatin capsule form. The soft elastic gelatin capsules are preferably formulated with from about 0.25 mg to about 250 mg of (R)-clidinium, more preferably with from about 0.50 mg to about 100 mg of (R)-clidinium, and even more preferably with from about 1 mg to about 50 mg of (R)-clidinium.

Actual dosage levels of (R)-clidinium in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

5 The selected dosage level and frequency of administration will depend upon a variety of factors including the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the (R)-clidinium, the age, sex, weight, condition, general health and prior medical history of the patient being  
10 treated, and like factors well known in the medical arts. For example, the dosage regimen is likely to vary with pregnant women, nursing mothers and children relative to healthy adults.

15 A physician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician could start doses of the compound employed in the pharmaceutical composition of the present invention at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

20 A suitable daily dose of (R)-clidinium will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, the total daily dose of (R)-clidinium for the conditions described herein may be from about 0.25 mg to about 500 mg, more preferably from about 0.50 mg to about 250 mg, and more preferably from about 1 mg to about 100 mg.

25 If desired, the effective daily dose of the active (R)-clidinium may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

30 Another embodiment of the present invention relates to a kit for treating urinary incontinence, including, e.g., bladder detrusor muscle instability incontinence, stress incontinence, urge incontinence, overflow incontinence, enuresis, and post-prostatectomy incontinence, wherein said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof,

and a pharmaceutically acceptable carrier, and instructions for administering enantiomerically enriched (R)-clidinium for the treatment of urinary incontinence while reducing or eliminating anticholinergic adverse effects associated with racemic clidinium or other incontinence drugs with anticholinergic action.

5 The utility of (R)-clidinium may be established by the following studies of antimuscarinic, spasmolytic, and calcium entry blocking effects in models of receptor binding and bladder function.

Binding to Human M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub> Muscarinic Receptor Subtypes

10 These experiments are carried out on membranes prepared from SF9 cells infected with baculovirus to express the human recombinant M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub> muscarinic receptor subtypes. The binding assays are performed as set forth in Table 1.

Table 1

Receptor	Radioligand	Conc.	Nonspecific	Incubation time/temp.	Reference Compound
M <sub>1H</sub>	[ <sup>3</sup> H]pirenzepine	2nM	atropine (1μM)	60 min/27°C	pirenzepine
M <sub>2H</sub>	[ <sup>3</sup> H]IAF-D <sup>X</sup> 384	2nM	atropine (1μM)	60 min/27°C	methoctramine
M <sub>3H</sub>	[ <sup>3</sup> H]4-DAMP	0.8nM	atropine (1μM)	60 min/27°C	4-DAMP
M <sub>4H</sub>	[ <sup>3</sup> H]4-DAMP	0.3nM	atropine (1μM)	60 min/27°C	4-DAMP
M <sub>5H</sub>	[ <sup>3</sup> H]4-DAMP	0.5nM	atropine (1μM)	60 min/27°C	4-DAMP

20 Following incubation, the assays are rapidly filtered under vacuum through GF/B glass fiber filters (available, e.g., from Whatman) and washed with an ice-cold buffer using a Brandel Cell Harvester. Bound radioactivity is determined with a liquid scintillation counter (e.g., LS6000, Beckman) using a liquid scintillation cocktail (e.g., Formula 99, DuPont NEN).

25 The compounds are tested on each receptor at 10 concentrations in duplicate to obtain competition curves. In each experiment, the reference compound for the receptor under investigation is simultaneously tested at 8 concentrations in duplicate to obtain a competition curve in order to validate this experiment.

The specific radioligand binding of each receptor is defined as the difference between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand. IC<sub>50</sub> values (concentrations required to inhibit 50% of specific binding) are determined by non linear regression analysis of the competition curves. These 5 parameters are obtained by curve fitting using SigmaPlot™ software.

Binding to Calcium Channels

Binding assays are performed using the methods set forth in Table 2.

Table 2

Receptors	Membranes	Reference Compounds	References
Ca channel (T + L, diltiazem site)	rat cerebral cortex	diltiazem	Schoemaker and Langer (1985)
Ca channel (T + L, verapamil site)	rat cerebral cortex	D600	Reynolds et al (1986)

The experiment conditions are set forth in Table 3.

Table 3

Receptors	Ligands	Concentrations	Nonspecific	Incubation
Ca channel (T + L, diltiazem site)	[ <sup>3</sup> H] diltiazem	5nM	diltiazem (10μM)	120 min 25°C
Ca channel (T + L, verapamil site)	[ <sup>3</sup> H]D 888	0.5 nM	D 600 (10μM)	60 min 22°C

Following incubation, the assays are rapidly filtered under vacuum through GF/B or GF/C glass fiber filters (available, e.g., from Whatman) and washed with an ice-cold buffer using a Brandel Cell Harvester. Bound radio-activity is determined with a liquid scintillation counter (e.g., LS 6000, Beckman) using a liquid scintillation cocktail (e.g., 25 Formula 989, DuPont NEN).

The compounds are tested in duplicate on each receptor at a concentration of 10<sup>5</sup>M. In each experiment, the reference compound for the receptor under investigation is simultaneously tested at 8 concentrations in duplicate to obtain a competition curve in order to validate this experiment.

30 The specific radioligand binding of each receptor is defined as the difference

between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand. Mean values are expressed as a percentage of inhibition of specific binding.  $IC_{50}$  values (concentration required to inhibit 50% of specific binding) are determined by non linear regression analysis of their competition curves. These 5 parameters are obtained by curve fitting using SigmaPlot<sup>TM</sup> software.

Functional Characterization of Antimuscarinic/Antispasmodic Activity

The effects of (R)-clidinium are studied in an *in vitro* model of bladder function. For example, isolated strips of guinea pig bladder smooth muscle are mounted in a tissue 10 bath and contracted either with the muscarinic agonist carbachol or with increasing concentrations of external potassium.

**Bladder strips.** Experiments are performed using methods similar to those described by Kachur *et al.* (*J. Pharmacol. Exp. Ther.*, 247:867-872 (1988)) and Noronha-Blob and Kachur (*J. Pharmacol. Exp. Ther.*, 256:562-567 (1991)). Strips of tissue 15 (approximately 10 mm long and 1.5 mm wide) are removed from the body of the urinary bladder of male guinea pigs weighing 400-600 g. (available, *e.g.*, from Elm Hill Breeding Laboratories, Chelmsford, MA). The tissues are suspended in an oxygenated buffer of the following composition, in mM: NaCl, 133; KCl, 4.7; CaCl<sub>2</sub>, 2.5; MgSO<sub>4</sub>, 0.6; NaH<sub>2</sub>PO<sub>4</sub>, 1.3; NaHCO<sub>3</sub>, 16.3; and glucose, 7.7. The tissues are maintained at 37.5° C. Isometric contractions of the tissues are recorded by using appropriate transducers and an 20 ink-writing polygraph. A resting tension of 0.5 grams is maintained on each tissue at all times.

Individual tissues are allowed to equilibrate with the bathing solution for one hour before proceeding with the experiment.

**Carbachol-induced contractions.** These series of experiments focus on 25 anticholinergic actions. In these experiments, in order to assess the viability of each tissue and to serve as a frame of reference, the contractions of each strip of tissue are recorded initially in response to exposure to a tissue medium in which the NaCl is replaced by KCl to yield a concentration of 137.7 mM KCl in the medium. This is followed by return to the standard medium, and then by exposure to progressively increasing concentrations of 30 carbachol, with separate exposure to each concentration only until the peak response has been recorded.

Then, leaving one strip untreated and/or one strip exposed to a vehicle to serve as control tissue(s), the remaining strips each are exposed for one hour to one concentration of an antagonist. The vehicle controls are used when, because of poor solubility, stock solutions of the test substances are prepared in a vehicle, *e.g.*, ethanol. Finally, the 5 responses to increasing concentrations of carbachol followed by exposure to 137.7 mM KCl are recorded a second time.

**Potassium-induced contractions.** These experiments focus on the spasmolytic action of the substances being studied. Contractions are recorded in response to sequentially increasing the concentration of potassium in the medium.

10 To determine whether test substances decrease the peak response to agonists, the peak tension developed by each strip during the second set of determinations is expressed as a percent of the peak tension developed during the first concentration-effect determination. Then, for each test substance the resultant data are analyzed for treatment-related differences by one-way analysis of variance (ANOVA). Since only one 15 concentration of test substance is studied in each strip of bladder, the procedures of Arunlakshana and Schild (1959) are used in modified form to estimate the pA2 and slope of the Schild regression.

First, the concentrations of agonist producing a half-maximal response (the EC<sub>50</sub>) is estimated for each strip from the second set of concentration-effect data. The EC<sub>50</sub> is 20 obtained from linear regression lines fit to the logarithm of the concentration of drug and the responses bracketing the half maximum level of response. For each drug-treated strip, a "concentration ratio" (CR) is calculated as the ratio of the EC<sub>50</sub> of the treated tissue divided by the EC<sub>50</sub> of the untreated tissue. For each experiment where two or more strips are exposed to the same test substance but at different concentrations, the logarithm of 25 this ratio minus one [*i.e.*, log (CR-1)] is plotted against the logarithm of the concentration of antagonist to which the strip had been exposed to produce "Schild plots". A regression analysis relating log(CR-1) to the logarithm of the concentration of the antagonist is employed to estimate the pA2 and the slope of the regression line.

Finally, experiments are grouped by test substance and the mean  $\pm$  S.E. of the pA2 30 and slope are calculated. The 95% confidence limits (CL) for the slope are estimated from its S.E. using standard methods. For experiments in which only one strip is exposed

to a given test substance, a pKD is calculated as (concentration of antagonist)/(CR-1) and the negative logarithm of the KD is then pooled with the pA2 values to yield an expanded set of pA2 values.

5 The embodiments of the present invention described above are intended to be merely exemplary and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. All such equivalents are considered to be within the scope of the present invention and are covered by the following claims.

10 The contents of all references described herein are hereby incorporated by reference.

Other embodiments are within the following claims.

What is claimed is:

1. A method for treating urinary incontinence, comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof.
2. The method as recited in Claim 1, wherein the enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising said enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. The method as recited in Claim 2, wherein said pharmaceutical composition is administered by oral, parenteral, transdermal, rectal, or vaginal administration.
4. The method as recited in Claim 3, wherein said pharmaceutical composition is administered by oral administration.
5. The method as recited in Claim 3, wherein said pharmaceutical composition is administered by parenteral administration.
6. The method as recited in Claim 2, wherein said pharmaceutical composition is administered by injection.
7. The method as recited in Claim 2, wherein said pharmaceutical composition is administered by intravesical perfusion.
8. The method as recited in Claim 1, wherein a daily amount of (R)-clidinium administered in the preparation is about 0.25 mg to about 500 mg.
9. The method as recited in Claim 8, wherein the daily amount of (R)-clidinium administered in the preparation is about 0.50 mg to about 250 mg.
10. The method as recited in Claim 9, wherein the daily amount of (R)-clidinium administered in the preparation is about 1 mg to about 100 mg.
11. The method as recited in Claim 2, wherein (R)-clidinium comprises greater than 50 % by weight of the total clidinium in said pharmaceutical composition.
12. The method as recited in Claim 11, wherein (R)-clidinium comprises at least 75 % by weight of the total clidinium in said pharmaceutical composition.
13. The method as recited in Claim 12, wherein (R)-clidinium comprises at least 80 % by weight of the total clidinium in said pharmaceutical composition.

14. The method as recited in Claim 1, wherein (R)-clidinium is administered as a pharmaceutical composition comprising substantially enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. The method as recited in Claim 14, wherein (R)-clidinium comprises at least 85 % by weight of the total clidinium in said pharmaceutical composition.

16. The method as recited in Claim 15, wherein (R)-clidinium comprises at least 90 % by weight of the total clidinium in said pharmaceutical composition.

17. The method as recited in Claim 16, wherein (R)-clidinium comprises at least 95 % by weight of the total clidinium in said pharmaceutical composition.

18. The method as recited in Claim 17, wherein (R)-clidinium comprises at least 99 % by weight of the total clidinium in said pharmaceutical composition.

19. The method as recited in Claim 1, wherein the subject is treated for stress incontinence.

20. The method as recited in Claim 1, wherein the subject is treated for urge incontinence.

21. The method as recited in Claim 1, wherein the subject is treated for post-prostatectomy incontinence.

22. The method as recited in Claim 1, wherein the subject is treated for enuresis.

23. A method for treating bladder detrusor muscle instability, said method comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof.

24. The method as recited in Claim 23, wherein said enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, is substantially free of (S)-clidinium.

25. A pharmaceutical composition, comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

26. The pharmaceutical composition as recited in Claim 25, wherein (R)-clidinium comprises greater than 50 % by weight of the total clidinium in said

pharmaceutical composition.

27. The pharmaceutical composition as recited in Claim 26, wherein (R)-clidinium comprises at least 75 % by weight of the total clidinium in said pharmaceutical composition.

28. The pharmaceutical composition as recited in Claim 27, wherein (R)-clidinium comprises at least 80 % by weight of the total clidinium in said pharmaceutical composition.

29. The pharmaceutical composition as recited in Claim 25, wherein said pharmaceutical composition is formulated for oral administration.

30. The pharmaceutical composition as recited in Claim 25, wherein said pharmaceutical composition is formulated for administration by injection.

31. The pharmaceutical composition as recited in Claim 25, wherein said pharmaceutical composition is formulated for administration by intravesical perfusion.

32. The pharmaceutical composition as recited in Claim 25, wherein the amount of (R)-clidinium present in said pharmaceutical composition is about 0.25 mg to about 500 mg.

33. The pharmaceutical composition as recited in Claim 32, wherein the amount of (R)-clidinium present in said pharmaceutical composition is from about 0.50 mg to about 250 mg.

34. The pharmaceutical composition as recited in Claim 33, wherein the amount of (R)-clidinium present in said pharmaceutical composition is from about 1 mg to about 100 mg.

35. The pharmaceutical composition as recited in Claim 25, wherein enantiomerically enriched (R)-clidinium comprises from about 1 % to about 99 % of the total pharmaceutical composition.

36. The pharmaceutical composition as recited in Claim 35, wherein enantiomerically enriched (R)-clidinium comprises from about 5 % to about 70 % of the total pharmaceutical composition.

37. The pharmaceutical composition as recited in Claim 36, wherein enantiomerically enriched (R)-clidinium comprises from about 10 % to about 30 % of the total pharmaceutical composition.

38. A pharmaceutical composition, comprising (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)-clidinium, and a pharmaceutically acceptable carrier.

39. The pharmaceutical composition as recited in Claim 38, wherein (R)-clidinium comprises at least 85 % by weight of the total clidinium in said pharmaceutical composition.

40. The pharmaceutical composition as recited in Claim 39, wherein (R)-clidinium comprises at least 90 % by weight of the total clidinium in said pharmaceutical composition.

41. The pharmaceutical composition as recited in Claim 40, wherein (R)-clidinium comprises at least 95 % by weight of the total clidinium in said pharmaceutical composition.

42. The pharmaceutical composition as recited in Claim 41, wherein (R)-clidinium comprises at least 99 % by weight of the total clidinium in said pharmaceutical composition.

43. The pharmaceutical composition as recited in Claim 38, wherein said pharmaceutical composition is formulated for oral administration.

44. The pharmaceutical composition as recited in Claim 38, wherein said pharmaceutical composition is formulated for administration by injection.

45. The pharmaceutical composition as recited in Claim 38, wherein said pharmaceutical composition is formulated for administration by intravesical perfusion.

46. The pharmaceutical composition as recited in Claim 38, wherein the amount of (R)-clidinium present in said pharmaceutical composition is about 0.25 mg to about 500 mg.

47. The pharmaceutical composition as recited in Claim 46, wherein the amount of (R)-clidinium present in said pharmaceutical composition is from about 0.50 mg to about 250 mg.

48. The pharmaceutical composition as recited in Claim 47, wherein the amount of (R)-clidinium present in said pharmaceutical composition is from about 1 mg to about 100 mg.

49. The pharmaceutical composition as recited in Claim 38, wherein substantially enantiomerically enriched (R)-clidinium comprises from about 1 % to about 99 % of the total pharmaceutical composition.

50. The pharmaceutical composition as recited in Claim 49, wherein substantially enantiomerically enriched (R)-clidinium comprises from about 5 % to about 70 % of the total pharmaceutical composition.

51. The pharmaceutical composition as recited in Claim 50, wherein substantially enantiomerically enriched (R)-clidinium comprises from about 10 % to about 30 % of the total pharmaceutical composition.

52. A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.

53. The pharmaceutical unit dosage form as recited in Claim 52, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 0.25 mg to about 250 mg.

54. The pharmaceutical unit dosage form as recited in Claim 53, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 0.50 mg to about 100 mg.

55. The pharmaceutical unit dosage form as recited in Claim 54, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 1 mg to about 50 mg.

56. A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.

57. A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.

58. The pharmaceutical unit dosage form as recited in Claim 57, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 0.25 mg to about 250 mg.

59. The pharmaceutical unit dosage for as recited in Claim 58, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 0.50 mg to about 100 mg.

60. The pharmaceutical unit dosage for as recited in Claim 59, wherein said enantiomerically enriched (R)-clidinium is present in an amount of about 1 mg to about 50 mg.

61. A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.

62. Enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof.

63. (R)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of (S)-clidinium.

64. A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering enantiomerically enriched (R)-clidinium for the treatment of urinary incontinence while reducing or eliminating concomitant liability of adverse effect.

65. The kit as recited in Claim 64, wherein said adverse effect is one or more of drowsiness, epistaxis, xerostomia, mydriasis, cycloplegia, cardiovascular tachycardia, cardiovascular palpitations, increased ocular pressure, nausea, constipation, decreased sweating, impotence, or unwanted dermal manifestations.

66. A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising substantially enantiomerically enriched (R)-clidinium, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering substantially enantiomerically enriched (R)-clidinium for the treatment of urinary incontinence while reducing or eliminating concomitant liability of adverse effects.

67. The kit as recited in Claim 65 wherein said adverse effect is one or more of drowsiness, epistaxis, xerostomia, mydriasis, cycloplegia, cardiovascular tachycardia, cardiovascular palpitations, increased ocular pressure, nausea, constipation, decreased sweating, impotence, or unwanted dermal manifestations.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/11258

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/435; C07D 453/02  
 US CL : 514/305; 546/133

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/305; 546/133

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, APS, MEDLINE

search terms: clidinium, incontinence, bladder

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WEIN, A.J. PHARMACOLOGIC THERAPY FOR INCONTINENCE. SUPPLEMENT TO UROLOGY, OCTOBER 1990, VOL. 36, NO. 4, PAGES 36-43, ESPECIALLY TABLE II ON PAGE 38.	1-67
Y	US 3,714,357 A (CLAUDE ET AL.) 30 JANUARY 1973, EXAMPLE 1 IN COL. 2, LINES 30-42 AND COL. 15, LINES 38-72.	1-67
Y	US 4,644,003 A (RZESZOTARSKI ET AL.) 17 FEBRUARY 1987, COL. 2, LINES 5-53; COL. 5, LINES 25-68 AND COL. 6, LINES 1-65.	1-67
A	US 5,519,033 A (ROSEN ET AL.) 21 MAY 1996, CLAIM 1.	1-67

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:			
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

31 AUGUST 1997

Date of mailing of the international search report

29 OCT 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHANAKUZAKI

Telephone No. (703) 308-1235